Interpace Biosciences (IDXG) investor relations material

Company overview and business model

• Provides esoteric molecular diagnostic testing and pathology services focused on cancer risk evaluation, primarily for thyroid and previously pancreatic cancers.

• Commercializes genomic tests, notably ThyGeNEXT® and ThyraMIR® v2, for indeterminate thyroid nodules, with a strong focus on personalized medicine.

• Customers include physicians, hospitals, cancer centers, commercial labs, and clinics; major revenue channels are Medicare, Medicaid, and commercial payers.

• Developing new molecular diagnostic tests for pancreatic cyst and Barrett's Esophagus cancer risk, with pancreatic test launch dependent on CMS reimbursement.

• Holds CLIA certification, CAP accreditation, and New York State approval for its laboratory operations.

Financial performance and metrics

• ThyGeNEXT® and ThyraMIR® v2 revenue grew at a 19.7% CAGR from 2022 to 2025, reaching $34.8M in 2025.

• Gross profit for thyroid diagnostics increased from $10.9M in 2022 to $21.2M in 2025.

• Adjusted EBITDA improved from $(4.9)M in 2022 to $4.4M in 2025.

• Net income attributable to common stockholders was $24.6M in 2025, with $0.89 basic EPS after the reverse split.

• As of June 30, 2026, net tangible book value was $4.20 per share, with $23.2M in cash and cash equivalents.

Use of proceeds and capital allocation

• Estimated net proceeds of $17.9M ($20.8M if over-allotment is exercised) will be used for working capital, capital expenditures, and general corporate purposes.

• A portion may fund development of new tests for pancreatic cyst and Barrett's Esophagus cancer risk, and potential acquisitions or investments in complementary businesses.

• No current commitments for acquisitions or investments.